早期子宮內膜乳突狀漿液性腺癌的檢視

The role of adjuvant therapy in women with stage I papillary serous adenocarcinoma of the endometrium

乳突狀漿液性子宮內膜癌是一種十分惡性的子宮內膜癌，預後差，死亡率高。建議 患者應接受完整分期手術，並輔以化學和放射線治療。最近分子醫學研究顯示，此 疾病含很高比例HER 2/neu和P53的異常，其預後更差，日後需更多標靶治療藥物中， 冀求較好的療效。

Uterine papillary serous adenocarcinoma is the most aggressive endometrial cancer, representing less than 10% of all cases, a disproportionate number of deaths and poor prognosis. Patients should receive complete surgical staging. Recently, we advocate for combination chemotherapy and radiotherapy as adjuvant treatment given the poor outcomes in thes patients. In molecular profile, it has a high rate of P53 alterations and HER 2/neu alternations. Targeted therapies are warranted for women with this biologically aggressive variant of endometrial cancer in future.